Q-omics provides the consensus-scored PNPLA5 profile across patient tissues and cancer cell-line models. PNPLA5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, PNPLA5 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PNPLA5 RNA expression shows 9,772 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THYM, THCA, and GBM as cancer lineages where PNPLA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNPLA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNPLA5 survival associations across molecular data types. PNPLA5 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNPLA5 RNA expression–survival associations across cancer types. High PNPLA5 expression shows unfavorable associations in THYM, UCEC, KIRC, OV, LUAD and COAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for PNPLA5 RNA expression.
This table summarizes PNPLA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PNPLA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNPLA5 shows lower tumor expression in COAD and higher tumor expression in THCA, UCEC, LUAD, LUSC and HNSC. The THCA box plot shows higher PNPLA5 RNA expression in tumor versus normal tissue (log2 FC = +2.025, t-test p < 0.001).
This table shows molecular features associated with PNPLA5 in patient tissues and cancer cell lines. In patient samples, PNPLA5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNPLA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
